Jiangsu gdk Biotechnology Co., Ltd. Class A

As of June 30, 2026, Jiangsu gdk Biotechnology Co., Ltd. Class A carries a market capitalization of 2.09B, placing it among publicly traded companies globally. Its enterprise value stands at 2.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Jiangsu gdk Biotechnology Co., Ltd. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Jiangsu gdk Biotechnology Co., Ltd. Class A has 123.20M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 53.37, and the price-to-book ratio stands at 1.99.

These figures are as of June 30, 2026. The EV/Sales ratio of 51.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.02B versus a market cap of 2.09B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Jiangsu gdk Biotechnology Co., Ltd. Class A maintains a current ratio of 1.57, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.84, indicating elevated leverage, while an interest coverage ratio of -91.73 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Jiangsu gdk Biotechnology Co., Ltd. Class A posted a negative return on equity (ROE) of -14.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.65, reflecting losses generated across the asset base. The company generates approximately 96,662.84 in revenue per employee across its workforce of 405.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.37 indicates how many times Jiangsu gdk Biotechnology Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Jiangsu gdk Biotechnology Co., Ltd. Class A recorded an income tax benefit of -2.70M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -167.85M and -165.14M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Jiangsu gdk Biotechnology Co., Ltd. Class A's stock has declined approximately 20.44% over the past 52 weeks. The 50-day moving average sits at 16.35, while the 200-day moving average is 17.49.

Over the twelve months ended June 30, 2026, Jiangsu gdk Biotechnology Co., Ltd. Class A generated 39.20M in revenue and converted that into -165.14M in net income, yielding earnings per share of -1.34. EBITDA reached -168.10M, while operating income came in at -156.03M.

As of June 30, 2026, Jiangsu gdk Biotechnology Co., Ltd. Class A holds 190.43M in cash and equivalents against 124.05M in total debt, resulting in a net debt position of 58.12M. Total book value stands at 1.05B, with working capital of 111.73M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Jiangsu gdk Biotechnology Co., Ltd. Class A posted a gross margin of 54.62, reflecting its pricing power and cost economics. The operating margin of -398.07 and net profit margin of -421.30 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Jiangsu gdk Biotechnology Co., Ltd. Class A paid dividends of 0.01 per share. The dividend payout ratio of -1.08 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -3.51, meaning Jiangsu gdk Biotechnology Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Jiangsu gdk Biotechnology Co., Ltd. Class A's most recent stock split took place on May 26, 2023 with a 5:7 split ratio.

As of June 30, 2026, Jiangsu gdk Biotechnology Co., Ltd. Class A has an Altman Z-Score of 4.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.